Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Leukemia and Lymphoma

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10428194.2016.1267349PMID 27967286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proteasome inhibitor associated thrombotic microangiopathy

  2016cited by this paper
• Outcomes of patients with renal monoclonal immunoglobulin deposition disease

  2016cited by this paper
• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

  2016cited by this paper
• Natural history and outcome of light chain deposition disease.

  2015influential reference
• Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.

  2015influential reference
• Diagnosis of monoclonal gammopathy of renal significance.

  2015cited by this paper
• A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

  2014cited by this paper
• Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?

  2014cited by this paper
• How I treat monoclonal gammopathy of renal significance (MGRS).

  2013cited by this paper
• Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution.

  2012influential reference
• New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

  2012cited by this paper
• Autologous stem cell transplant for light chain deposition disease: Incorporating bortezomib to the induction therapy

  2012cited by this paper
• Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.

  2012cited by this paper
• Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement

  2012cited by this paper
• What do I need to know about immunoglobulin light chain (AL) amyloidosis?

  2012cited by this paper
• Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.

  2011cited by this paper
• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

  2011cited by this paper
• Treatment of light chain deposition disease with bortezomib and dexamethasone

  2009cited by this paper
• Proliferative glomerulonephritis with monoclonal IgG deposits.

  2009cited by this paper
• Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure

  2008cited by this paper
• Appraisal of immunoglobulin free light chain as a marker of response.

  2008cited by this paper
• Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

  2005cited by this paper
• Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.

  2003cited by this paper
• Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

  2002cited by this paper
• Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains

  2002cited by this paper
• Kidney and liver involvement in monoclonal light chain disorders.

  2002cited by this paper
• Renal monoclonal immunoglobulin deposition disease: the disease spectrum.

  2001cited by this paper
• Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells.

  1997cited by this paper
• Renal disease and patient survival in light chain deposition disease.

  1995cited by this paper

• Heavy Chain Deposition Disease in Monoclonal Gammopathy of Renal Significance: A Prodrome of Multiple Myeloma Case and Literature Review

  2025cites this paper
• Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus

  2025cites this paper
• Diagnosis of light‑chain deposition disease after renal transplantation: A case report and literature review

  2024cites this paper
• Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach

  2023cites this paper
• Multiple Myeloma Presenting as Acute Kidney Failure Secondary to Lambda Light Chain Deposition

  2022cites this paper
• Clinicopathologic characteristics and prognostic analysis of monoclonal gammopathy of renal significance (MGRS) in patients with IgM monoclonal gammopathy: a case series

  2022cites this paper
• Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors

  2022cites this paper
• A case of light chain deposition disease involving the kidney with a normal serum free kappa/lambda light chain ratio

  2022cites this paper
• Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management

  2021cites this paper
• Case Report: Lenalidomide as a Second-Line Treatment for Bortezomib-Ineffective Nephrotic Syndrome Caused by LCDD: 2 Case Reports and a Literature Review

  2021cites this paper
• Monoclonal Gammopathy of Renal Significance.

  2021cites this paper
• Evidence-based recommendations for the management of symptoms and care for patients with multiple myeloma

  2020cites this paper
• MGRS: clinical manifestation, pathogenic characteristic and treatment.

  2020cites this paper
• 单克隆免疫球蛋白沉积病的诊治进展

  2020cites this paper
• Kidney involvement in monoclonal gammopathies: multidisciplinary approach in oncohematology and nephrology

  2020cites this paper
• Clinical and morphological spectrum and long-term outcome in monoclonal gammopathy of renal significance: one center study

  2020cites this paper
• [Monoclonal gammopathy of renal significance: consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment].

  2019cites this paper
• Long term outcomes in monoclonal gammopathy of renal significance

  2019cites this paper
• The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

  2018cites this paper
• Dysproteinemias and Glomerular Disease.

  2018cites this paper
• The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and monoclonal gammopathy of renal significance.

  2018cites this paper
• Renal, GI, and Peripheral Nerves: Evidence‐based recommendations for the management of symptoms and care for patients with multiple myeloma

  2017cites this paper
• Demystifying the Monoclonal Gammopathies of Renal Significance

  2017cites this paper
• New Horizons in Nephrology: Update in Onco-Nephrology

  2017cites this paper
• Disease and Symptom Care: A Focus on Specific Needs of Patients With Multiple Myeloma
.

  2017cites this paper